Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIM joint venture
Cambridge, United Kingdomaimjv.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AIM (Advanced Inhalation Medicine) is a strategic joint venture established between AstraZeneca, Ionis Pharmaceuticals, and MedImmune to develop novel inhaled therapies for respiratory diseases. The collaboration leverages Ionis's antisense technology and AstraZeneca's expertise in respiratory medicine to create targeted treatments for conditions such as asthma and chronic obstructive pulmonary disease (COPD). By focusing on the delivery of antisense oligonucleotides directly to the lungs, the venture aims to modulate disease-driving proteins with high precision. The partnership represents a significant effort to advance the next generation of inhaled genetic medicines.
- Therapeutic areas
- Pulmonology
- Modalities
- Antisense oligonucleotideSmall molecule
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on AIM joint venture.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIM joint venture.